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Abstract
Background: There is a lack of consensus in the addiction treatment literature regarding the definition of
substance abuse “recovery”.
Methods: This study utilized a review of the literature together with a participatory research design to construct a
conceptual model of recovery from the perspectives of addiction treatment professionals, those recovering from
addictions, and researchers.
Results: A multidimensional, comprehensive hypothetical model consisting of seven conceptual domains (physical,
biomarker, psychological, psychiatric, chemical dependency, family/social, and spiritual) is presented. Each domain
is operationally defined by identifying reliable and valid instruments that may be used to measure the domain. It is
proposed that the conceptual model be tested using confirmatory factor analysis.
Conclusions: If empirically supported, this conceptual model would validate the hypothesized multidimensional
nature of recovery and provide a potential means for assessing recovery in future treatment outcome studies.
Background
The field of addiction treatment lacks a universally
accepted and unambiguously defined clinical definition
of recovery. Although a single disciplinary group such as
physicians may agree upon a definition, there is no such
agreement among the broader field of treatment profes-
sionals, addiction researchers, program evaluators, and
policymakers. Indeed, there is no comprehensive con-
sensus of what a definition of “recovery” is even among
those individuals who are themselves in recovery from
substance use disorders [1,2].
There have been many efforts to define recovery from
substance use disorders. Perhaps the most often used
criteria for remission from substance use disorders by
treatment professionals are those from the Diagnostic
and Statistical Manual of Mental Disorders (DSM)[ 3 ] .
An example of such a criterion is the sum of all years in
which a diagnosis of alcohol use disorder was not pre-
sent. However, this criterion indicates a remission from
a clinical diagnosis, rather than a multidimensional per-
spective on recovery.
Perhaps the most comprehensive efforts to define
“recovery” were those offered by leading investigators as
part of a special issue on “recovery” published by the
Journal of Substance Abuse Treatment (October 2007).
Methodological approaches to developing a definition of
recovery included a consensus panel, literature reviews,
surveys of the general public and addiction treatment
professionals, and opinions from persons themselves in
“recovery”.
The Betty Ford Consensus Panel [4] defined “recov-
ery” as consisting of three parts: sobriety, personal
health, and citizenship. Sobriety refers to abstinence
from alcohol and all other non-prescribed drugs; perso-
nal health refers to improved quality of health; and citi-
zenship refers to living with regard and respect for
others. This conceptualization has come under criticism
for several reasons, including the use of the construct of
citizenship as a measure of chemical dependency recov-
ery. The objection is that no other chronic illness is
measured for recovery status on the construct of citizen-
ship [5]. The Betty Ford panel proposed measuring
recovery using the World Health Organization Quality
of Life instrument. However, this approach has been cri-
tiqued on the ground that a measure developed for a
general population may not be valid for the specific
population of people in recovery [5]. Arndt & Taylor [5]
view the Betty Ford conceptualization as an initial step
in defining “recovery,” rather than the pinnacle of a
definition.
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cess and sustained status) through which individuals,
families and communities impacted by severe alcoholism
and other drug problems utilize internal and external
resources to voluntarily resolve these problems, heal the
wounds inflicted by alcohol and other drug-related pro-
blems, and develop a healthy, meaningful and produc-
tive life. White [7] subsequently proposed outcome
measures for these areas including measures of
substance use, living environment, physical and
emotional health, family relationships, citizenship, and
quality of life.
Laudet [1] cites a survey of members of the public
regarding their view of recovery (Peter D. Hart Research
Associates, 2004). This survey indicated that 62%
reported that “in recovery from addiction to alcohol or
other drugs, the one addicted is trying to stop using”.
Only 22% of respondents reported that “the one in
recovery is free from the disease of addiction and no
longer uses alcohol or illicit drugs”. Further, 80% of
respondents expressed that total abstinence was their
“recovery” goal and over 80% reported that “recovery” is
ap r o c e s sa n dn o taf i n i t ea c h i e v e m e n t .A p a r tf r o mt h e
public’s perceptions, Laudet [1] also conducted a review
of articles on recovery and concluded that most
researchers operationally define recovery in terms of
substance use and more often as abstinence status.
Some of the terms used interchangeably were remission,
resolution, abstinence, and recovery. In addition, words
to represent the act of changing the substance using
behaviors were quit, overcome, and recover.I nt h e s e
contexts, “recovery” is defined as “overcoming both phy-
sical and psychological dependence to psychoactive
drugs while making a commitment to society.” This
description implies domains of recovery that encompass
drug abstinence, personal wellbeing, and re-integration
into society.
Galanter [8] suggested a model of “recovery” from
addiction that is attuned with the spiritual framework sup-
ported by Alcoholics Anonymous. This aspect of recovery
is based on the substance-using individuals’ own perspec-
tives. These experiences are not observable; rather, they
are self-reported through the persons’ interpretations. This
is an important domain of “recovery” and is reminiscent of
the spiritual orientation of Alcoholics Anonymous.
Finally, McLellan, Chalk, & Bartlett [9] present “recov-
ery” in terms of outcomes, performance, and quality.
Calls for accountability within the addiction treatment
field have inspired these authors to build a set of treat-
ment quality, performance and outcome indicators.
They suggest that outcomes of any treatment are the
changes in clients’ symptoms, behaviors, and functioning
that can be attributed to the treatment. Because clients
present with multiple problems, outcome evaluations of
chemical dependency treatment have measured more
than one outcome variable. Outcome measures are gen-
erally grouped together by the domain of functioning
that they represent. When clients experience abstinence
or a substantial reduction in use of drugs/alcohol as
well as improvement in functioning in other domains
(e.g., family, social, education, financial, etc.) this can be
called “recovery.” The three variables that are most fre-
quently presented as “recovery” domains are substance
use, employment/self-support, and criminal activity. The
Substance Abuse and Mental Health Services Adminis-
tration [10] measures substance abuse “recovery” by
adjoining physical health, mental health, family and
social relations, stability in housing, perception of care,
access, and retention domains. According to SAMSHA,
improvements in three of the seven functional domains
plus abstinence are considered indicative of “recovery”.
As can be seen from the above, the definition and very
concept of recovery is unclear, although a convergence
of ideas is beginning to emerge. It might be fundamental
to consider the foregoing efforts, which represent collec-
tive federal agency/consensus panel/empirical definitions
of “recovery” as a starting point meant to be reviewed,
revised, expanded upon, revisited, and updated. There-
fore, the purpose of this article is to move toward an
abstinence-based model of recovery by using existing
models and developing upon them. This article is theo-
retical in nature and does not present quantitative ana-
lyses. Instead it presents the results of a small
qualitative effort meant to create a theoretical founda-
tion for future research.
Methods
This study used a participatory approach to explore
“recovery” from the perspectives of addiction treatment
professionals. It used inductive content analysis
approaches to identify domains of recovery that could
be modeled for further testing.
Setting
The study was conducted at the Hanley Center, a private,
82-bed residential substance abuse treatment facility
located in South Florida. The Hanley center serves a pri-
marily white, private-pay clientele. The facility has sepa-
rate treatment centers for men, women, and older adults.
Comprehensive assessment and services are provided
based on an eclectic model including medical, 12-step,
cognitive/behavioral, and spiritual approaches delivered
in individual, family, and small group modalities.
Participants
T h e r ew e r ee l e v e np a r t i c i p a n t s .E i g h to ft h e s ew e r e
managers of their respective disciplines at the Hanley
Center, and three were researchers. The following
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among the eight managers: medicine (physician and
nurse); psychiatry; psychology; clinical therapy; social/
emotional wellness; family/community; and spirituality.
The multidisciplinary approach was used in order to
obtain a comprehensive perspective on recovery. The
researchers, who had expertise in addiction, research
methodology, and neuroscience, lent their empirically-
centered guidance to the process. Some of these partici-
pants were in recovery themselves. The participants
included both men and women, all had a master’so r
doctorate degree in their discipline, and most had
worked in the field of substance abuse for more than
ten years.
Procedures
The participants convened in group discussions at the
Hanley Center over the period of one year to review lit-
erature, review the instruments used to collect data
from Hanley clients, discuss practice observations and
experiences, and derive findings in a prioritization pro-
cess to define “recovery” and select measures to indicate
the attainment of “recovery.” The researchers solicited
and encouraged the managers/practitioners to induc-
tively construct domains from the ground up to repre-
sent dimensions of “recovery.” Their responses were
then merged with the existing literature to determine
overlaps of concepts and reconcile differences in order
to formulate a collective operational definition of “recov-
ery” and select instruments that measure it.
Results
The literature review and group discussion process led
to the conclusion that a single industry-wide definition
of “recovery” did not exist and that the multiple defini-
tions that did exist were usually subjective and open for
interpretation and often appeared more ideological than
scientific. As a result of this process and conclusions,
the participants inductively constructed seven domains
that represent aspects, and are sensitive to status, of
“recovery": physical; bio-marker; chemical dependency;
psychological; psychiatric; family/social; and spiritual.
This conceptual model is summarized in Table 1. For
each conceptual domain, potential operational measures
are proposed. Some of these measures were already in
use at the Hanley Center at the time of the group dis-
cussions, but others were not and were selected based
on the literature review.
The model is holistic in that all the domains are
hypothesized to be correlated with each other and all
are considered important to recovery. However, it
should be noted that not all domains will be relevant to
all clients. For example, some addiction clients have
co-occurring physical and psychological impairments
wherein improvement may not be expected, and thus
these domains would not be relevant elements of recov-
ery for these individuals.
Definitions and Measurement of Domains
Each of the domains is defined below and the instru-
ments that may be used to measure it are identified. All
identified instruments have established reliability and
validity.
Physical Domain
Recovery is indicated in part by improvement in overall
physical health. This may be measured by a history and
physical examination, blood panels, brain imaging, and
self-report. History, physical exam, and blood panels
may be used to measure general signs, symptoms, and
chemistries indicative of health and illness. Brain ima-
ging using scans such as SPECT, PET, MRI, and func-
tional MRI may be used to assess the effects of abused
substances on the brain. Finally, the self-report medical
health subscale of the Addiction Severity Index (ASI)
[11] may be used to measure the physical domain.
Bio-Marker Domain
Kraemer, Schultz, & Arndt [12] have defined a biomar-
ker as a measurable characteristic of living tissues that
indicates whether a specific event or process of medical
Table 1 Conceptual Model of Substance Abuse Recovery
Conceptual
Domain
Potential Operational Measures
Physical History and Physical
Urine Chemistry Panel
Brain Imaging
ASI Medical Subscale
Bio-Marker Neuropeptides: Orexin, Oxytocin
Cortisol
Chemical
Dependency
ASI Alcohol/Drug Use Subscales
Urine and Breath Screening
Psychological MMSE or TONI-3
Shipley
Psychiatric DSM-IV-TR Axis I
ASI Psychiatric Health Subscale
Family/Social ASI: Employment/Self-Support, Family Relations, Illegal
Activity Subscales
MMPI-2: Work Interference, Family Problems,
Antisocial Practices Scales
Spiritual Spirituality Self-Rating Scale
ASI-JCAHO Spirituality Scale
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Frank & Hargreaves [13] define a biomarker as a charac-
teristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic pro-
cesses, or pharmacological responses to a therapeutic
intervention. The common theme captured in the defi-
nitions above is that biomarkers can provide readily
accessible information regarding an individual’sd i s e a s e
state.
We propose that relevant biomarkers for measuring
recovery include neuropeptides and hormones. Specifi-
cally, we propose that the neuropeptides that may be
used as indicators of substance use disorders and
recovery are orexin (also known as hypocretin) and
oxytocin. Neuropeptide transmitters are made exclu-
sively in hypothalamic neurons and have extensive
central nervous system projections. Harris & Aston-
Jones [14] reveal a novel and important role for the
orexin/hypocretin neuronal system in reward proces-
sing and addiction. The hypothalamus has been con-
sidered essential in motivational behaviors. Orexin is
expressed in the lateral hypothalamus and has been
implicated in the regulation of feeding behavior. Neu-
rons expressing this neuropeptide have extensive pro-
jections to regions of the brain vital to behavioral
responses to drugs of abuse, raising the possibility
that these pathways are central when examining
addiction [15,16].
Some neuropeptides affect adaptive central nervous
system processes related to opiate, ethanol, and cocaine
addiction. Oxytocin, a neuropeptide synthesized in the
brain and released at the posterior pituitary, is also
released in the central nervous system. Oxytocin acts
within the CNS to inhibit the development of tolerance
to morphine. The behavioral tolerance to the effect of
cocaine was inhibited by oxytocin while increasing beha-
vioral sensitivity to cocaine. Tolerance to ethanol was
also inhibited by oxytocin [17].
A hormone that may be measured to indicate recovery
is cortisol. It has been determined that addiction
patients appear to be biologically different from healthy
subjects as indicated by greater cortisol blunting and
other cortisol-related hormonal and psychological
responses [18]. In fact, during early drug-quitting
phases, cortisol levels were found to drop and be related
to withdrawal distress and could be found to be asso-
ciated with the attainment of abstinence [19,20].
Chemical Dependency Domain
This domain represents the extent to which the indivi-
dual uses addictive chemicals. It may be measured using
the alcohol and drug use subscales of the ASI, and urine
and breath screening. A five panel urine quick screen
m a yb ea d m i n i s t e r e dt ot e s tf o rb e n z o d i a z e p i n e s ,
amphetamines, cocaine, THC and opiates. If the result
is positive a quantitative test may be conducted to test
for ethanol, amphetamine, barbiturate, benzodiazepines,
cannabinoids, cocaine (metabolite), opiates, phencycli-
dine, methadone, propoxyphene, meperidine, and trama-
dol. A breathalyzer may be utilized for alcohol testing.
Psychological Domain
Many persons suffering from addiction enter treatment
i nas i g n i f i c a n t l yc o g n i t i v e ly impaired state. Thus,
improvement in gross cognitive functioning is indicative
of recovery. Basic cognitive functioning may be mea-
sured with one of two instruments: the Folstein Mini-
Mental State Examination (MMSE) [21] or the Test of
Nonverbal Intelligence (TONI-3) [22]. The MMSE
assesses orientation, registration, attention and calcula-
tion, recall, and language. Alternatively, the TONI-3 is
administered to persons who have a cognitive impair-
ment or who speak a language other than English. The
test requires no reading, writing, speaking, or listening
by the participant. Cognitive impairment in individuals
with normal intelligence can be assessed using the Ship-
ley Institute of Living Scale [23].
Psychiatric Domain
This domain refers to the presence of a mental disorder.
This may be measured by a diagnosis on Axis I of the
Diagnostic and Statistical Manual of Mental Disorders
[3]. Recovery would be indicated by a diagnosis of a dis-
order in remission. This domain may also be measured
by the psychiatric health subscale of the ASI, which cap-
tures a somewhat different aspect of psychiatric func-
tioning than does the DSM diagnosis.
Family/Social Domain
This domain includes interaction with family and
engagement with community. It may be measured
using the employment/self support, family relations,
and illegal activity subscales of the ASI, and the Work
Interference, Family Problems, Antisocial Practices
Scales of the Minnesota Multiphasic Personality Inven-
tory-2 (MMPI-2) [24].
Spiritual Domain
This domain reflects the wide usage of Alcoholics
Anonymous and other 12-step programs in the addic-
tion rehabilitation community. It is defined as how an
individual’s way of life is reflected in thinking, speaking,
and acting and the quality of one’s relationships with
oneself, others, and with a Higher Power. Spirituality
may be measured with the Spirituality Self-Rating Scale
[25] and the Spirituality Scale of the ASI-JCAHO Ver-
sion [26].
Testing the Model
The next step in this research process is to test the
hypothesized conceptual model. Such a test would
involve collecting data using all of the proposed instru-
ments at intake into a treatment program and at
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collection, confirmatory factor analysis would be used to
examine (1) the extent to which the proposed measur-
able indicators are representative of their respective con-
ceptual domains, (2) the extent to which changes in the
indicators occur over time; and (3) the extent to which
the conceptual domains are correlated with each other
initially and over time.
Confirmatory factor analysis would yield both an esti-
mation of how well the model fit the data, and tests of
specific hypotheses. For purpose (1) above, the null
hypothesis is that each of the indicators within a domain
are not correlated with each other. If so, this would
demonstrate an absence of an underlying concept. How-
ever, if the null hypothesis were rejected, it would sug-
gest that there is construct validity of the underlying
concept or domain. For purpose (2), the null hypothesis
would be that the indicators do not change over time as
individuals proceed through the treatment and aftercare
process. Rejection of the null hypothesis would suggest
that these indicators are in fact indicative of recovery.
For purpose (3), the null hypothesis is that the concep-
tual domains are not correlated; rejection would suggest
convergent validity of the model. Additionally, this
model could be further validated by correlating propen-
sity scores derived from the model with clinicians’ inde-
pendent ratings of the clients’ degree of recovery (i.e.,
known-groups validity).
As a result of this validation process, it is likely that
the model would be refined. Some of the indicators may
turn out not to adequately represent their respective
domains (i.e., indicators not correlated with their
domains), and some of the domains may turn out not to
adequately represent recovery (i.e., domains not corre-
lated with other domains). Thus, the model would likely
be reduced through empirical testing. Individual compo-
nents of the domains and biomarkers would need to be
checked for sensitivity and specificity which would
address effect size issues.
Discussion and Conclusions
This study has several limitations that should be noted.
First, the participants represented a narrow selection of
experts. Second, the study site, the Hanley Center,
serves a fairly demographically homogeneous treatment
population, which might bias the experts’ views. Third,
some of the conceptual domains have more support in
t h et r e a t m e n tl i t e r a t u r et h a no t h e r s ;f o re x a m p l e ,t h e
biomarker domain primarily has research but not treat-
ment support; however the aim of the proposed model
is to test the treatment support for this domain.
This conceptual model represents an initial effort to
build upon and expand upon traditional biopsychosocial
models of addiction such as the syndrome model
proposed by Schaffer et al. [27]. The syndrome model
proposes a common etiology (e.g., distal antecedents
such as neurobiology and proximal antecedents such as
biopsychosocial events) that creates multiple expressions
of the disease of addiction such as drug and alcohol
misuse, gambling, smoking, psychiatric co-morbidities,
social misconduct and biological malfunctioning. The
syndrome model describes addiction. This paper pro-
poses a potential model of recovery by incorporating
elements of the syndrome model and reversing this pro-
cess to build a model of recovery. The recovery model
proposes that the reversal of addiction can be captured
biologically through the measurement of neuroadapta-
tions and hormonal shifts, and psychosocially with
paper and pencil measures across the chemical depen-
dency, psychiatric, psychological, family/social, and spiri-
tual domains.
Additionally, the proposed model expands upon tradi-
tional biopsychosocial models by adding the bio-marker
domain and the spiritual domain. In testing the bio-
marker domain, neuropeptides and neuroadaptations
may be examined to identify certain genes, DNA and
core RNA for biological elements that are diagnostic of
addiction, representative of recovery, and predictive of
relapse. Additionally, cortisol may be examined to see if
there are relationships between this hormone, stress,
addiction, and recovery. Adding the spiritual domain
incorporates the work of Galanter [8] who looks at
addiction and recovery by examining how spiritual inter-
ventions can be used to support recovery efforts.
If the hypothesized conceptual model is supported by
empirical data, it could provide a starting point for the
development of a comprehensive, unifying perspective of
recovery and its measurable indicators that could poten-
tially be used to assess recovery in future outcome stu-
dies. This model would yield a conception of recovery
as a continuum, rather than as a dichotomy (i.e., a per-
son is either in recovery or not). In this model, the
greater the improvement over time on a greater number
of indicators, the greater the “recovery” would be con-
sidered to be. Additionally, a validated unifying model
could provide a common metric across treatment pro-
grams that could allow for direct comparisons of
effectiveness.
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